Verified Nov 2026
Other
·
Gaithersburg, Maryland
·
Since 1998
Emergent BioSolutions is a biopharmaceutical company headquartered in Gaithersburg, Maryland, founded in 1998 and publicly traded under the ticker EBS. It employs between 500 and 1,000 people and reports revenue of about $742.9 million. The company develops, manufactures, and supplies medical countermeasures for infectious diseases and biodefense, and serves government agencies, healthcare providers, military customers, and pharmaceutical partners. In March 2026 it announced a contract award of over $60 million with the U.S. government for smallpox medical countermeasures.
Emergent BioSolutions at a glance
Revenue
742.9M
Employees
500-1,000
Founded
1998
Headquarters
Gaithersburg, Maryland
Ownership
Publicly traded (NYSE: EBS)
Import activity
247
Industries
Automotive
Electric Vehicles
Medical
Military & Defense
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
247
Named foreign suppliers
15
Top origins
France · Belgium · Netherlands · Germany
Shared foreign counterparties do not establish that these companies buy from Emergent BioSolutions.
What this tells a buyer
Emergent BioSolutions reported a $22.3 million delivery order modification in November 2026 to supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of War.
Its product portfolio includes the FDA-approved anthrax vaccine BioThrax and the opioid overdose treatment Narcan, along with vaccines for smallpox and cholera.
The company operates three segments (Commercial Product, Medical Countermeasures Product, and Bioservices) and is listed on the public market.
Source: US customs bill-of-lading records and public filings · Last verified Nov 05, 2026
Overview
Emergent BioSolutions is a biopharmaceutical company headquartered in Gaithersburg, Maryland, founded in 1998 and publicly traded under the ticker EBS. It employs between 500 and 1,000 people and reports revenue of about $742.9 million. The company develops, manufactures, and supplies medical countermeasures for infectious diseases and biodefense, and serves government agencies, healthcare providers, military customers, and pharmaceutical partners. In March 2026 it announced a contract award of over $60 million with the U.S. government for smallpox medical countermeasures.
At a glance
Attribute | Detail |
|---|---|
Founded | 1998 |
Headquarters | Gaithersburg, Maryland |
Employees | 500-1,000 |
Revenue | 742.9M |
Ownership | Publicly traded (NYSE: EBS) |
What Emergent BioSolutions makes
Its product portfolio includes the FDA-approved anthrax vaccine BioThrax and the opioid overdose treatment Narcan, along with vaccines for smallpox and cholera.
Products and capabilities described on the company's own site include LED (source: emergentbiosolutions.com).
Trade and customs footprint
Emergent BioSolutions reported a $22.3 million delivery order modification in November 2026 to supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of War. US customs bill-of-lading records list 247 inbound shipments across 15 foreign suppliers, with top origins including France · Belgium · Netherlands · Germany.
Latest developments
2026-11-04 — Emergent Biosolutions Inc. - Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War (emergentbiosolutions.com)
2026-09-15 — Emergent Biosolutions Inc. - Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility (emergentbiosolutions.com)
2026-09-03 — Emergent Biosolutions Inc. - Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes (emergentbiosolutions.com)
2026-04-28 — Emergent Biosolutions Inc. - Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States (emergentbiosolutions.com)
2026-03-25 — Emergent Biosolutions Inc. - Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures (emergentbiosolutions.com)
2026-02-26 — Emergent Biosolutions Inc. - Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness (emergentbiosolutions.com)
Company details
The company operates three segments (Commercial Product, Medical Countermeasures Product, and Bioservices) and is listed on the public market. Emergent BioSolutions was founded in 1998, has an estimated 500-1,000 employees, and is headquartered in Gaithersburg, Maryland.
Frequently asked questions
What does Emergent BioSolutions do?
Emergent BioSolutions is a biopharmaceutical company headquartered in Gaithersburg, Maryland, founded in 1998 and publicly traded under the ticker EBS. It employs between 500 and 1,000 people and reports revenue of about $742.9 million. The company develops, manufactures, and supplies medical countermeasures for infectious diseases and biodefense, and serves government agencies, healthcare providers, military customers, and pharmaceutical partners. In March 2026 it announced a contract award of over $60 million with the U.S. government for smallpox medical countermeasures.
Where is Emergent BioSolutions headquartered?
Emergent BioSolutions is headquartered in Gaithersburg, Maryland (300 Professional Dr, Gaithersburg, Maryland, 20879-3419).
When was Emergent BioSolutions founded?
Emergent BioSolutions was founded in 1998.
How big is Emergent BioSolutions?
Emergent BioSolutions has an estimated 500-1,000 employees, with revenue in the 742.9M range.
Is Emergent BioSolutions publicly traded?
Publicly traded (NYSE: EBS). Public financial figures are drawn from its filings.
Does Emergent BioSolutions import from overseas suppliers?
US customs bill-of-lading records show 247 inbound shipments for Emergent BioSolutions, with top origins including France · Belgium · Netherlands · Germany.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.